---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-25-000007"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:54:55.883279+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q4 XDEMVY sales $66.4M; full-year $180.1M; net loss narrows to $0.60/share

## Summary
- Q4 net product sales $66.4M (vs $13.1M YoY); full-year $180.1M (vs $14.7M), with 163,000 bottles dispensed in 2024.
- Net loss $23.1M ($0.60/share) in Q4 vs $41.9M ($1.31) in Q4 2023; full-year loss $115.6M ($3.07) vs $135.9M ($4.62).
- Cash and marketable securities $291.4M as of Dec 31, 2024; gross-to-net discount ~45% on XDEMVY.
- Pipeline: TP-04 for ocular rosacea on track to start Phase 2 in H2 2025; TP-05 for Lyme disease Phase 2 study planned.
- Appointed Dr. Elizabeth Yeu as CMO and Dr. Katherine Goodrich to Board of Directors.

## SEC filing metadata
- accession: 0001819790-25-000007
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979025000007/0001819790-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979025000007/tars-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-25-000007
- JSON: https://secwatch.observer/filing/0001819790-25-000007.json
- Plain text: https://secwatch.observer/filing/0001819790-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.